Breast Cancer

, 17:9 | Cite as

Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies

  • Hiroyuki Takei
  • Masafumi Kurosumi
  • Takashi Yoshida
  • Yuko Ishikawa
  • Yuji Hayashi
  • Jun Ninomiya
  • Katsunori Tozuka
  • Hanako Oba
  • Kenichi Inoue
  • Shigenori Nagai
  • Yoshihiro Saito
  • Tomoko Kazumoto
  • Jun-ichi Saitoh
  • Toshio Tabei
Special Feature Pitfalls in sentinel lymph node biopsy

Abstract

Background

It is currently unclear which patients with breast cancer with sentinel lymph node (SLN) metastases do not need axillary lymph node dissection (ALND).

Patients and methods

A cohort of 1,132 women who had unilateral invasive breast cancer with clinically negative nodes or nodes suspicious for metastasis, were intraoperatively diagnosed as having negative SLNs, and did not undergo an immediate ALND. Our intraoperative histological investigation uses H&E staining of a frozen section from a maximum cut surface of each SLN. Of these 1,132 women, 132 (11.7%) were postoperatively diagnosed as having positive SLNs, which classifies them as having an intraoperative, false-negative SLN biopsy (SLNB). Patient and tumor characteristics, treatment methods, and the prognoses of these patients were investigated and compared with the remaining 1,000 patients who were negative for SLNB.

Results

Of the 132 patients with intraoperative, false-negative SLNB, none underwent a further ALND. With a median follow-up period of 58.1 months, none of these patients exhibited recurrence in the axillary nodes. Their recurrence-free survival rates were not statistically different from those of patients with negative SLNB.

Conclusions

ALND can be avoided in most patients with breast cancer with intraoperative, false-negative SLNB.

Keywords

Breast cancer Sentinel lymph node biopsy (SLNB) Intraoperative false-negative SLNB Axillary lymph node dissection Recurrence 

Abbreviations

ALND

Axillary lymph node dissection

CI

Confidence interval

IDC NOS

Invasive ducal carcinoma not otherwise specified

ITCs

Isolated tumor cells

LVI

Lymphovascular invasion

SLN

Sentinel lymph node

SLNB

Sentinel lymph node biopsy

RT

Radiation therapy

References

  1. 1.
    Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2007;7:983–9.CrossRefGoogle Scholar
  4. 4.
    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. National surgical adjuvant breast and bowel project, technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Takei H, Suemasu K, Kurosumi M, Uchida K, Igarashi K, Ninomiya J, et al. Sentinel lymph node biopsy without axillary dissection after an intraoperative negative histological investigation in 358 invasive breast cancer cases. Breast Cancer. 2002;9:344–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Takei H, Suemasu K, Kurosumi M, HoriiY Yoshida T, Ninomiya J, Yoshida M, et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer. 2007;14:16–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Takei H, Kurosumi M, Yoshida T, Ninomiya J, Hagiwara Y, Kamimura M, et al. Current trends of sentinel lymph node biopsy for breast cancer—a surgeon’s perspective. Breast Cancer. 2007;14:362–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20:230–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Fant JS, Grant MD, Knox SM, Livingston SA, Ridl K, Jones RC, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate complete axillary dissection. Ann Surg. 2004;239:859–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Jeruss JS, Winchester DJ, Sener SF, Brinkmann EM, Bilimoria MM, Barrera E Jr, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241:152–8.PubMedGoogle Scholar
  14. 14.
    Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different? Surgery. 2008;143:641–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.Google Scholar
  17. 17.
    Takei H, Kurosumi M, Yoshida T, Ninomiya J, shikawa Y, Hayashi Y, Tozuka K, Asakawa H, Oba H, Inoue K, Tabei T. Positive sentinel lymph node biopsy predicts the number of metastatic axillary nodes of breast cancer. Breast. 2009 [Epub ahead of print].Google Scholar
  18. 18.
    Alkhatib W, Connor C, Fang F. Solitary positive sentinel lymph node accompanied by negative sentinel lymph node(s) in predictive of a negative completion axillary lymph node dissection. Am J Surg. 2007;194:856–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Rivers AK, Griffith KA, Hunt KK, Degninm AC, Sabel MS, Diehl KM, et al. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol. 2006;13:36–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.CrossRefPubMedGoogle Scholar
  24. 24.
    Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS 3rd. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Takei H, Suemasu K, Kurosumi M, Horii Y, Ninomiya J, Kamimura M, et al. Added value of the presence of blue nodes or hot nodes in sentinel lymph node biopsy of breast cancer. Breast Cancer. 2006;13:179–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Takei H, Suemasu K, Kurosumi M, Ninomiya J, Horii Y, Inoue K, et al. 99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer. Surg Today. 2006;36:219–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin. 2006;56:37–47.CrossRefPubMedGoogle Scholar
  28. 28.
    Kurosumi M, Suemasu K, Tabei T, Inoue K, Matsumoto H, Sugamata N, et al. Relationship between existence of lymphatic invasion in peritumoral breast tissue and presence of axillary lymph node metastasis in invasive ductal carcinoma of the breast. Oncol Rep. 2001;8:1051–5.PubMedGoogle Scholar
  29. 29.
    Takei H, Suemasu K, Kurosumi M, Horii Y, Ninomiya J, Yoshida M, et al. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer. Breast J. 2006;12(Suppl 2):S157–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol. 2009;16:113–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Spruit PH, Siesling S, Elferink MA, Vonk EJ, Hoekstra CJ. Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol. 2007;2:40.CrossRefPubMedGoogle Scholar
  34. 34.
    Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS + RT). Int J Radiat Oncol Biol Phys. 2006;66:1320–7.PubMedGoogle Scholar
  35. 35.
    Galper S, Recht A, Silver B, Bernardo MV, Gelman R, Wong J, et al. Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys. 2000;48:125–32.CrossRefPubMedGoogle Scholar
  36. 36.
    Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, et al. Tangential radiotherapy without axillary surgery in early stage breast cancer: results of a prospective trial. Int J Radiat Oncol Biol Phys. 2008;72:866–70.PubMedGoogle Scholar
  37. 37.
    Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, et al. Relationship of sentinel and axillary level I–II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51:671–8.PubMedGoogle Scholar
  38. 38.
    European Organization for Research and Treatment of Cancer. Phase III randomized study of complete axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node positive women with operable invasive breast cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00014612.

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Hiroyuki Takei
    • 1
  • Masafumi Kurosumi
    • 2
  • Takashi Yoshida
    • 1
  • Yuko Ishikawa
    • 1
  • Yuji Hayashi
    • 1
  • Jun Ninomiya
    • 1
  • Katsunori Tozuka
    • 1
  • Hanako Oba
    • 2
  • Kenichi Inoue
    • 3
  • Shigenori Nagai
    • 3
  • Yoshihiro Saito
    • 4
  • Tomoko Kazumoto
    • 4
  • Jun-ichi Saitoh
    • 4
  • Toshio Tabei
    • 3
  1. 1.Division of Breast SurgerySaitama Cancer CenterSaitamaJapan
  2. 2.Department of PathologySaitama Cancer CenterSaitamaJapan
  3. 3.Division of Breast OncologySaitama Cancer CenterSaitamaJapan
  4. 4.Department of RadiologySaitama Cancer CenterSaitamaJapan

Personalised recommendations